Autolus Therapeutics plc Operating Lease Liability
Autolus Therapeutics plc (AUTL) had Operating Lease Liability of $83.51 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability $83.51M.
- 2026-03-31: Operating Lease, Liability $79.96M.
- 2025-12-31: Operating Lease, Liability $71.39M.
- 2025-09-30: Operating Lease, Liability $65.83M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $83.51M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $79.96M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $71.39M 10-K · filed 2026-03-27 |
| 2025-09-30 | $65.83M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $64.53M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $57.71M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $52.63M 10-K · filed 2026-03-27 |
| 2024-09-30 | $52.23M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $50.02M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $51.34M 10-Q · filed 2024-05-17 |
| 2023-12-31 | $52.97M 10-K · filed 2025-03-20 |
| 2023-09-30 | $52.46M 10-Q · filed 2023-11-09 |
| 2022-12-31 | $24.26M 10-K · filed 2024-03-21 |
| 2021-12-31 | $21.00M 20-F · filed 2023-03-07 |
| 2020-12-31 | $54.16M 20-F · filed 2022-03-10 |
| 2019-12-31 | $26.22M 20-F · filed 2021-03-04 |
| 2019-09-30 | $26.69M 6-K · filed 2019-11-07 |
| 2019-06-30 | $27.42M 6-K · filed 2019-08-08 |
| 2019-01-01 | $6.30M 20-F · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |